Angiotensin-converting enzyme inhibition but not angiotensin II type 1 receptor antagonism augments coronary release of tissue plasminogen activator in hypertensive patients
Tetsuya Matsumoto, MD*,*,
Kazuo Minai, MD*,
Hajime Horie, MD*,
Naoto Ohira, MD*,
Hiroyuki Takashima, MD*,
Yasuhiro Tarutani, MD*,
Y. o Yasuda, MD*,
Tomoya Ozawa, MD*,
Shinro Matsuo, MD*,
Masahiko Kinoshita, MD* and
Minoru Horie, MD*
* First Department of Internal Medicine, Shiga University of Medical Science, Seta Tsukinowa, Otsu, Shiga, Japan
View larger version (23K):
[in a new window]
|
Figure 1 The effects of bradykinin (0.2, 0.6, and 2.0 µg/min) and papaverine (PA) (12 mg) on mean arterial pressure (upper panel) and heart rate (lower panel) in the control group (solid circles), perindopril group (solid triangles), and losartan group (open squares). *p < 0.05 versus baseline.
|
|
View larger version (25K):
[in a new window]
|
Figure 2 The effects of bradykinin (0.2, 0.6, and 2.0 µg/min) and papaverine (PA) (12 mg) on percent changes in coronary blood flow and vascular resistance in the control group (solid circles), perindopril group (solid triangles), and losartan group (open squares).
|
|
View larger version (17K):
[in a new window]
|
Figure 3 The effects of bradykinin (0.2, 0.6, and 2.0 µg/min) and papaverine (PA) (12 mg) on tissue-type plasminogen activator (t-PA) antigen in the aorta (Ao) and coronary sinus (CS) in the control group (solid circles), perindopril group (solid triangles), and losartan group (open squares). *p < 0.05 versus baseline.
|
|
View larger version (21K):
[in a new window]
|
Figure 4 The effects of bradykinin (0.2, 0.6, and 2.0 µg/min) and papaverine (PA) (12 mg) on net tissue-type plasminogen activator (t-PA) release in the control group (solid circles), perindopril group (solid triangles), and losartan group (open squares). *p < 0.05 versus baseline.
|
|
View larger version (16K):
[in a new window]
|
Figure 5 The effects of bradykinin (0.2, 0.6, and 2.0 µg/min) and papaverine (PA) (12 mg) on plasminogen activator inhibitor type 1 (PAI-1) antigen in the aorta (Ao) and coronary sinus (CS) in the control group (solid circles), perindopril group (solid triangles), and losartan group (open squares).
|
|
|
